Quick take
Quick take (July 2026): for a UK clinician this is already decided — OpenEvidence withdrew from the UK and EU in April 2026, while BMJ Best Practice is free to NHS staff in England, Scotland, and Wales through national funding. Where both are reachable, OpenEvidence suits recent-literature questions and BMJ suits UK pathway wording. Neither is a reasoning tool.
Who each one is for
The fastest way to rule one out. Both are good products — they are built for different people.
OpenEvidence
- Who is it for
- Who it’s for: Verified U.S. clinicians
- Best for
- Best for: Fast questions about recent literature
- Cost
- Cost: $0
- Free: No subscription — funded by pharmaceutical advertising.
- Speed: Built for a single question answered in seconds.
- Primary literature: Answers cite peer-reviewed papers directly.
You are a verified U.S. clinician asking about recent primary literature. OpenEvidence is free, fast, and grounded in peer-reviewed sources — but note it is not an option in the UK or EU at all since April 2026.
- Verification centres on a U.S. National Provider Identifier, which excludes most non-U.S. physicians and nearly all students.
- Withdrew from the European Union and the United Kingdom in April 2026, citing regulatory uncertainty including the EU AI Act.
- Advertising-funded, shows no reasoning, retains no encounter context, and has no public developer API.
BMJ Best Practice
- Who is it for
- Who it’s for: NHS staff in England, Scotland, Wales
- Best for
- Best for: UK pathway wording and defensibility
- Cost
- Cost: $0 for NHS staff; paid otherwise
- Free on the NHS: Nationally funded for NHS staff and learners in England, Scotland, Wales.
- UK alignment: Summaries sit close to NICE and UK guideline framing.
- Structure: Step-through summaries that map onto management pathways.
You are UK-based, and especially if you are NHS staff in England, Scotland, or Wales, where it is already funded on your behalf. Its structured summaries align closely with UK pathway language, which matters for documentation and local defensibility.
- The free access is an NHS entitlement, not a general free tier — outside those schemes it is a normal paid subscription.
- Not an AI reasoning tool: no chain-of-thought, no encounter context, and no published accuracy benchmarks.
- English-only and UK-weighted, which is a strength locally and a limitation elsewhere.
OpenEvidence vs BMJ Best Practice: full comparison
Every cell is a checkable fact rather than a score, verified against vendor documentation in July 25, 2026. Sources are listed at the foot of the page.
| Dimension | OpenEvidence | BMJ Best Practice |
|---|---|---|
| Price (individual, 2026) | Free (funded by pharmaceutical advertising) | Free for NHS staff in England, Scotland, and Wales; paid subscription otherwise |
| Free tier | Yes | Yes, via NHS national funding |
| Verification required | U.S. NPI number required | OpenAthens or the relevant NHS national portal |
| Availability | U.S. only — withdrew from the EU and UK in April 2026 | Free in the UK via the NHS; subscription elsewhere |
| Languages | English | English |
| Source base | Peer-reviewed literature | BMJ editorial summaries and guidelines |
| Shows its reasoning | No — returns a cited answer without showing its reasoning | No |
| Ranked differential | No | Structured assessment guidance |
| AI scribe | No | No |
| Published benchmarks | None published by the vendor | None published |
| Developer API | No public self-serve developer API | Institutional integrations |
| Compliance posture | HIPAA, SOC 2 | NHS-approved deployments |
Which wins, by clinical job
“Which is better” has no answer until you say better at what. Here is a named winner for each job, including the 3 where OpenEvidence or BMJ Best Practice beats EvidenceMD.
| Clinical job | OpenEvidence | BMJ Best Practice | EvidenceMD |
|---|---|---|---|
| You are a UK clinician looking for a tool today | Unavailable — withdrew from the UK and EU in April 2026. | WinnerWinner. Free to NHS staff in England, Scotland, and Wales; BMA covers NI GPs. | Free to start in the UK with no gate, and adds transparent reasoning. |
| U.S. clinician asking about a recent trial | WinnerWinner. Free literature synthesis with citations, if you hold a U.S. NPI. | Curated summaries update on an editorial cycle, not from literature search. | Cites peer-reviewed sources and shows how each was weighed. |
| Following a settled management pathway | Fragmented for this — it answers questions rather than laying out a pathway. | WinnerWinner. Step-through summaries built to be followed, aligned to UK framing. | Produces a problem-based assessment and plan with cited reasoning. |
| Free AI reasoning that actually works in the UK | Not available in the UK at any price. | Free on the NHS, but a curated summary product rather than an AI reasoning tool. | WinnerWinner. Specialty-trained transparent reasoning, free to start, 30 languages. |
- You are a UK clinician looking for a tool today: BMJ Best Practice
- U.S. clinician asking about a recent trial: OpenEvidence
- Following a settled management pathway: BMJ Best Practice
- Free AI reasoning that actually works in the UK: EvidenceMD
What each costs over five years
Annual figures multiplied out, because a subscription decision is rarely for one year. Where a vendor publishes no individual price, we say so rather than estimating.
| Tool | Per year | Over 5 years | Free tier |
|---|---|---|---|
| OpenEvidence | $0 | $0 | Yes |
| BMJ Best Practice | $0 for NHS staff; paid otherwise | $0 for NHS staff | Yes, via NHS national funding |
| EvidenceMD | $0 to start | $0 to start | Yes |
Figures are list prices for an individual subscriber before tax, as published by each vendor in July 25, 2026. Institutional and group rates differ. Check for existing hospital or university access before buying anything individually.
A third option worth knowing about
The gap this pair exposes is regional. A UK clinician's free options shrank in April 2026, and BMJ Best Practice — excellent as it is — is a curated summary product rather than a reasoning tool. A free option that works in the UK and shows its reasoning is a genuinely different proposition.
EvidenceMD
The first transparent reasoning clinical decision support tool with chain-of-thought reasoning — specialty-trained, and free to start worldwide in 30 languages. Where OpenEvidence and BMJ Best Practice return an answer you have to take on trust, EvidenceMD is specialty-trained rather than a general model steered by a prompt, and it streams the clinical reasoning that produced the answer — so you can check the logic, not just the citation.
- Specialties fine-tuned on
- 40+Specialties fine-tuned on
- Thinking tokens, visible
- 64kThinking tokens, visible
- HealthBench Hard, SOTA
- 54.6%HealthBench Hard, SOTA
- Languages, worldwide
- 30Languages, worldwide
- Ranked differentialEach diagnosis carries its own reasoning and peer-reviewed citations, ordered by likelihood rather than listed flat.
- Assessment & planProblem-based, built from the same encounter rather than re-entered, so the plan traces back to the findings.
- Reasoning traceUp to 64,000 thinking tokens streamed step by step and auditable afterwards for review or teaching.
- Lab trend visualisationResults interpreted over time with trend charts and clinical significance flagging, not just current values.
- Clinical noteGenerated from the encounter with documentation integrity support, so the note reflects the reasoning.
- Cited clinical Q&AFollow-up questions answered in the context of this patient, with sources attached to each claim.
Where it does not replace BMJ Best Practice: It is not a licensed proprietary reference corpus. If your organisation mandates citations to UpToDate or Elsevier content specifically, you will still need that subscription alongside it.
OpenEvidence vs BMJ Best Practice: frequently asked questions
Is OpenEvidence available in the UK?
No. OpenEvidence withdrew from the United Kingdom and the European Union in April 2026, citing mounting regulatory uncertainty regarding the treatment of AI systems including the EU AI Act. This was a voluntary company decision rather than a regulatory ban, but the practical effect for UK clinicians is the same. UK clinicians looking for a free evidence-grounded tool should note that NHS staff in England, Scotland, and Wales already have BMJ Best Practice free through national funding, and that tools without a U.S. credential gate remain available.
What is the best free alternative to OpenEvidence in the UK?
There are two realistic routes. If you are NHS staff in England, Scotland, or Wales, BMJ Best Practice is free to you through national funding via OpenAthens or your national portal, and BMA-member GPs and GP trainees in Northern Ireland get 12 months free — this is a curated summary resource rather than a generative search tool. For an AI tool that reasons and cites and has no U.S. credential or regional gate, you need something built to be available globally. What you cannot do is access OpenEvidence itself, regardless of willingness to pay.
How do OpenEvidence and BMJ Best Practice differ in approach?
They are different categories. OpenEvidence is a generative tool that searches and synthesizes peer-reviewed literature in response to a natural-language question, so it reflects primary research including recent trials. BMJ Best Practice is an editorially curated set of structured clinical summaries organised around diagnosis and management steps, designed to be followed rather than queried conversationally. For a settled management pathway BMJ Best Practice is usually faster; for a question about new evidence a literature tool is better suited.
Does BMJ Best Practice align with NICE guidance?
BMJ Best Practice is UK-oriented and sits closer to NICE and UK guideline framing than U.S.-origin resources do, which is a large part of why the NHS funds it nationally. It is not the same thing as NICE or NICE CKS, however, and where UK pathway wording specifically matters for documentation or local defensibility, clinicians commonly check NICE or CKS directly. Treating BMJ Best Practice as broadly UK-aligned but verifying specific pathway language against NICE is the sensible working assumption.
Sources
Pricing and eligibility verified against vendor documentation in July 25, 2026. Subscription rates change — confirm current pricing with the vendor before purchasing.
- Wolters Kluwer: UpToDate subscription pricing — Vendor source for $579 standard, $699 Pro Plus with Expert AI, and $219 trainee.
- AMBOSS: official pricing documentation — Vendor source for the $19.99/$149 student and $29.99/$259 practitioner tiers.
- BMJ Best Practice: free access for NHS staff — Confirms national NHS funding in England, Scotland, and Wales.
- Elsevier: ClinicalKey AI — Confirms the institutional model, daily-refreshed corpus, and SMART on FHIR integration.
- EBSCO: DynaMedex — Confirms institutional and library licensing rather than published individual pricing.
- OpenEvidence exits the EU and UK over AI regulation — Reporting on the April 2026 withdrawal, citing the EU AI Act.